Spotlight on lanreotide Autogel in acromegaly.
Lanreotide Autogel (ATG) [Somatuline Depot]The use of trade names is for product identification purposes only and does not imply endorsement. is a novel, long-acting preparation of the somatostatin analog lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favorable pharmacokinetic profile that permits administration once every 28-42 days. Subcutaneous lanreotide ATG was an effective and generally well tolerated treatment in patients with acromegaly in well designed trials and extension studies of up to 4 years' duration. It was shown to be no less effective than intramuscular lanreotide long-acting (LA) microparticle treatment in these studies, with more limited data showing that lanreotide ATG therapy was as effective as intramuscular octreotide long-acting repeating (octreotide LAR) treatment. While both of these latter agents offer the advantage of treatment once every 28 days, lanreotide ATG also has the advantage of being available in a convenient pre-filled syringe and is given subcutaneously rather than intramuscularly like other somatostatin analogs. Thus it provides a valuable first-line option for the management of patients with acromegaly.
Croxtall
Jamie D
JD
Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz
Scott
Lesley J
LJ
D000172:Acromegaly / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D006801:Humans; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin